A Phase 4 interventional study of semaglutide and Metformin in Diabetes Mellitus, Cardiovascular Diseases and Cerebrovascular Disease, sponsored by China-Japan Friendship Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-05-07.
Sponsored by China-Japan Friendship Hospital · Phase 4, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies testing semaglutide in Diabetes Mellitus — 12 open to participants now, 14 under way, 2 of them phase 3. Semaglutide · Diabetes Mellitus.
Among the 82 studies testing semaglutide in Diabetes Mellitus, this one is the 35th largest by planned enrollment, is one of 5 that started in 2024, is one of 10 in phase 4, reaches primary completion later than 4 of the 13 other live ones, and was the 78th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →12 of the 82 studies testing semaglutide in Diabetes Mellitus are open now, in 8 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in Israel
Ages 18–64
Hospital Universitario Dr. Jose E. Gonzalez · Sites in Mexico
Ages 18+
Unity Health Toronto · Sites in Canada
Ages 18+
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–65
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 30 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 7 · Phase 3 27 · Phase 4 10
First in 2007; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 142 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 100 across the 82 interventional studies. Of the 66 that completed or were terminated, 28 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 82 have an industry lead sponsor. The 10 most frequent:
China-Japan Friendship Hospital is the lead sponsor of 179 studies on the registry; 112 are open to participants now.
China-Japan Friendship Hospital has 4 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
5 of the studies testing semaglutide in Diabetes Mellitus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05195944University Health Network, TorontoSemaglutide vs Sitagliptin | 2026-12 |
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT06959784China-Japan Friendship HospitalAssessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) | 2026-12-31 |
| NCT07401992Hospital Universitario Dr. Jose E. GonzalezEffects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | 2027-02-28 |
| NCT07017270Unity Health TorontoGlucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 82 studies testing semaglutide in Diabetes Mellitus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study used the diabetes prevention and follow-up research queue in Daqing and the public database of UKbiobank to evaluate the risk factors of cardiovascular and cerebrovascular events in diabetes patients, and built the first risk prediction model of cardiovascular and cerebrovascular events in diabetes patients based on the Chinese population follow-up queue and externally verified, so as to identify high-risk groups and guide the early prevention of cardiovascular and cerebrovascular diseases in diabetes patients. To evaluate the effect of incretin drugs on reducing the risk of cardiovascular and cerebrovascular events, and the impact on the remission rate of diabetes in people with initial diabetes, a randomized, multicenter, controlled clinical study was conducted. The long-term follow-up of 2 years was conducted to evaluate whether the cardiovascular and cerebrovascular risks of those who stopped drug treatment after remission of diabetes compared with those who continued drug treatment were reduced, as well as the long-term impact of incretin on cardiovascular and cerebrovascular risks and the role of long-term mitigation of diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The metformin control group received metformin (gradually increased to 1 g bid) for 24 weeks (6 months)
Drug: Metformin
The Semaglutide intervention group received semaglutide (starting at 0.25mg qw and increasing to 0.5mg qw after four weeks) for 24 weeks (6 months).
Drug: semaglutide
The semaglutide intervention group received semaglutide (0.25 mg qw initially, increased to 0.5 mg qw after four weeks) for 24 weeks (6 months).
The metformin control group was treated with metformin (gradually increasing to 1g bid) for 24 weeks (6 months)
Cardiovascular and cerebrovascular event risk score
The cardiovascular and cerebrovascular event score (0-100%)is based on the cardiovascular and cerebrovascular event risk prediction model for diabetic patients established in Objective 1. In this prediction model, age, gender, smoking status, body mass index, waist circumference, glycated hemoglobin, blood sugar, blood pressure, and blood lipids correspond to certain scores. Higher scores indicate a higher risk of cardiovascular and cerebrovascular events and a worse outcome.
Time frame: One-year follow-up
Major Adverse Cardiovascular Events
The Mace event includes cardiovascular death, non-fatal myocardial infarction and non-fatal stroke.
Time frame: Baseline and every 12 weeks until 96 weeks
Cerebrovascular disease events
Cerebrovascular diseases include ischemic stroke, hemorrhagic stroke, transient ischemic attack, cerebral vascular malformation, etc.
Time frame: Baseline and every 12 weeks until 96 weeks
The remission rate of diabetes
Time frame: at 9 months, 1 year and 2 years of follow-up
Glycated hemoglobin
Reduced levels of glycated hemoglobin
Time frame: Baseline and every 12 weeks until 96 weeks
Fasting and postprandial blood glucose levels
Time frame: at 2 year and 8 year of follow-up
pancreatic islet function
The study evaluated pancreatic islet cell function by testing fasting insulin, insulin one hour after a steamed bread meal, and insulin two hours after a steamed bread meal.
Time frame: Baseline, 48 weeks and 96 weeks
Heart rate
The heart rate of the subjects were measured by electrocardiogram when they were at rest.
Time frame: Baseline, 48 weeks and 96 weeks
Carotid artery peak systolic velocity
Evaluate the systolic peak blood flow velocity through carotid artery ultrasound.
Time frame: Baseline, 48 weeks and 96 weeks
Routine urine examination
Evaluate the levels of red blood cells, white blood cells, urine glucose, urine ketones, and urine protein in urine through urine routine testing.
Time frame: Baseline, 48 weeks and 96 weeks
Urine microalbumin
Urine microalbuminuria for early assessment of renal damage.
Time frame: Baseline, 48 weeks and 96 weeks
Heart rhythm
The heart rhythm of the subjects were measured by electrocardiogram when they were at rest.
Time frame: Baseline, 48 weeks and 96 weeks
Carotid artery peak diastolic velocity
Evaluate the diastolic peak blood flow velocity through carotid artery ultrasound.
Time frame: Baseline, 48 weeks and 96 weeks
Carotid resistance index
Evaluate resistance index through carotid artery ultrasound. Carotid resistance index = (peak systolic velocity - end diastolic velocity) / peak systolic velocity
Time frame: Baseline, 48 weeks and 96 weeks
common carotid artery diameter
Evaluate the common carotid artery diameter through carotid artery ultrasound.
Time frame: Baseline, 48 weeks and 96 weeks
Carotid artery wall thickness
Evaluate the wall thickness through carotid artery ultrasound.
Time frame: Baseline, 48 weeks and 96 weeks
Carotid Intima-media Thickness
Evaluate the intimal thickness through carotid artery ultrasound.
Time frame: Baseline, 48 weeks and 96 weeks
Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.
Of 149 non-industry phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 35 months is above that.
Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
China-Japan Friendship Hospital →